Three things to know:
1. The FDA approved the cervical artificial disc in 2012. Globus Medical designed the disc for reconstruction and motion perseveration at the operated disc level.
2. Globus Medical published a long term, seven-year clinical trial in the International Journal of Spine Surgery outlining the success of the Secure-C compared to traditional anterior cervical discectomy and fusion.
3. At seven-year post-operative follow-up, patients treated with Secure-C exhibited the following results compared to patients treated with ACDF:
• Statistically superior composite protocol-specified overall success results (86.3 percent vs. 70 percent)
• Statistically superior composite FDA-defined overall success results (79.2 percent vs. 63.6 percent)
• Greater percentage of patients with at least 25 percent improvement in Neck Disability Index (90.4 percent vs. 86 percent)
• Lower rate of subsequent surgery at the original treated level (4.2 percent vs. 15.3 percent)
• Lower rate of adjacent level surgery (4.2 percent vs. 16 percent)
More articles on devices and implants:
Nextech acquires EMR solution for orthopedic practices: 3 details
How China-US tariff tension affects orthopedic companies; Moody’s thinks they’ll adapt
3 things to know about AxioMed
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
